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866-3 Computer Vision in Echocardiography: Observer- 
Independent, Autonomous Echo Analysis Using 
Wavelet Footprints 
Christian H. Jansen, Muthuvel Arigovindan, Michael Siihling, Michael Unser, Stephan 
Marsch, Patrick Hunziker. University Hospital of Basel, Basel, Switzerland, Swiss 
Federal Institute of Technology, Lausanne, Switzerland 
Background: Echocardiography IS largely subjective with high observer dependence. 
Computer-assisted echo image analysis is demanding because of strong noise. absence 
of continuous boundaries and lack of constant intensities within objects. 
Method: Multidimensional multiscale wavelet analysis produces highly specific “foot- 
prints” from heart structures. We explolted this fact to create an automatic analysis enn- 
ronment that is based on shape and motion specific wavelet footprints of individual heart 
structures. TO test the feasibility of user-independent analysis, we applied the system for 
identification of the mitral valve autonomously in 182 echo loops. Gold standard for mitral 
valve location in the echo sequences was an experienced echocardiographer. 
Results: Autonomous analysis was successful in 165 of 182 ultrasound sequences COT- 
responding to 91% accuracy. The use of multidimensional multiscale footprints led to 
strong enhancement of the predefined structure (mitral valve, middle image) and signifi- 
cantly suppressed noise and non-related cardiac structures as shown in pixel statistics of 
the mitral valve region versus non related image parts (p < 0.05). yielding reliable auto- 
matic valve delineation (right image). 
Conclusion: Computer vision technology is applicable to clinical echo and allows 
obsenw-independent, automatic analysis of predefined cardiac structures, transforming 
the subjective and qualitative art of echo into a objective and quantitative science. 
866-4 Divx Compression Allows Medically Lossless lntranet 
or Internet Exchange of Coronary Angiograms 
Patrick Henry, Isaac Azancot, Lariboisiere, Paris, France 
Background: Coronary Angiograms (CA). even compressed, cannot be actually reason. 
ably sent via Internet networks due to their very large size. The aim of this study was to 
assess if DIVX compression can generate medically lossless dynamic sequences, and 
could permit the exchange of dynamic CA. 
Methods: We compared 30 random runs from 15 different CAlPTCAs by 13 independent 
blinded cardiologists. Two different DivX compression rates were analysed: the standard 
compression (StDivX) and an optimised compression (OpDivX) adapted for CA. For each 
run, the non compressed file (NCF) and each corresponding divX compressed file were 
simultaneously and randomly displayed on 2 identical monitors using the same video 
player. For each run the following score was gwen 0: no visual difference - 1: one 
screen aesthetically better - 2: small differences not clinically relevant - 3: differences 
eventually leading to misinterpretation - 4: major differences certainly leading to misinter- 
pretation. Results Compared to the non compressed files DtvX compressions induced a 
huge decrease in the file size of each run (mean size in MB: NCF: 55.2 - StDivX: 0.8 
OpDivX: 1.1). Table shows that the repartition of the scores between the corresponding 
390 NCF and DivX compressed video dynamic sequences was mainly 0 or 1 score with 
no 3 or 4 score for OpDivX. Conclusion : OpDivX compression is associated with a huge 
decrease in file size allowing IntraneVlntemet based video communication, while provid- 
ing medically lossless information. 
Standard DivX 
Optimized DivX 
DivX Better NCF Better 
4 3 2 1 0 1 2 3 4 
0% 0% 1% 7% 34% 44% 13% 1% 0% 
0% 0% 0% 10% 57% 31% 2% 0% 0% 
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871-l Modeling the Impact of Patient and Lesion 
Characteristics on the Cost-Effectiveness of Drug- 
Eluting Stents 
Dan Greenberg Ameet Bakhai, Nancy E. Neil, Ronna H. Berezin, Kalon K. Ho, Donald 
E. Cutlic. Richard E. Kuntz. David J. Cohen. Harvard Clinical Research Institute. Boston. 
MA, Be& Israel-Deaconess Medical Center; Boston, MA 
Drug-eluting stents (DES) are a promising technology for reducing restenosis after PCI. 
However, the cost-effectiveness (C/E) of these devices is unknown. Methods We used 
a decision-analytic model to project P-year costs and outcomes for patients undergoing 
single-vessel PCI, by either conventional stenting (CS) or DES. Angiographic restenosis 
rates with CS were estimated using a previously validated logistic regression model. 
Costs were assessed from a societal perspective. We assumed that 60% of patients with 
angiographic restenosis would require clinically driven target vessel revascularization 
and that DES would reduce restenosis rates by 90% at an incremental cost of $2,000/ 
stent. Results. C/E ratios were calculated as cost per repeat revascularization (RepRev) 
avoided and are displayed below (see Table). Compared with CS. DES was projected to 
have a C/E ratio < $10,000 per RepRev avoided (similar to other accepted PCI tech- 
niques) for patients with reference vessel diameters 4.0 mm and either lesion lengths 
215 mm 01 diabetes. DES was less attractive for patients with focal lesions in larger ves- 
sels (C/E ratio > $20,000 per RepRev avoided). Conclusions. At an incremental cost of 
$2,000 per stent, DES appears to be cost-effective for a large segment of patients under- 
going single vessel PCI. Lower incremental costs would render this technology cost say- 
ing for a wider target population. 
C/E ratio ($ per repeat revasculwization avoided) for diabetic and non-diabetlc patients 
Lesion Length (mm) 
Diabetic Patients 
Vessel diameter 10 
(mm) 
2.5 cost- 
saving 
3.0 3,748 
3.5 14,462 
4.0 38,328 
Non-Diabetic Patients 
2.5 1,320 
3.0 11,470 
36 29,387 
4.0 51,730 
15 20 25 
cost- 
saving 
1,320 
11,470 
29,387 
cost- cost- Cost- 
saving saving saving 
cost- cost- Cost- 
saving saving saving 
9,018 5,237 2,454 
22,996 18,198 11,470 
cost- cost- cost- 
saving saving saving 
9,018 5,237 2,454 
22,996 18,198 11,470 
51,730 38,328 29,387 
30 
316 
9,018 
22,996 
8:45 a.m. 
871-Z Safety of an Early Discharge Strategy Following 
Primary Intervention With Adjunctive Glycoprotein Ilbl 
llla inhibition: The CADILLAC Trial 
David E. Kandzari, James E. Tcheng, Cindy L. Grines, David J. Cohen, Ameet Bakhai. 
David A. Cox, Thomas D. Stuckey, Mark Effron. John J. Griffin, Mark Turco, John D. 
Carroll, Martin Fahy. Roxana Mehran. Gregg W. Stone, Duke Clinical Research Institute, 
Durham. NC, Cardiovascular Research Foundation. New York, NY 
Background- Early hospital discharge (D/C) following primaty percutaneous coronary 
intervention (PCI) for acute myocardial infarction (AMI) may be limited by early in-hospi- 
tal complications. Glycoprotein Ilb/llla inhibitors, by reducing early recurrent ischemia, 
may facilitate early D/C and reduce hospital costs. 
Methods- The CADILLAC trial randomized 2,082 patients (pts) with AMI to 1 of 4 reper- 
fusion strategies in a 2x2 factorial design: (1) PTCA (2) PTCA with abciximab (abcx), (3) 
stent implantation or (4) stenting with abcx. In pts randomized to abcx post procedural 
heparin was withheld, and D/C was scheduled on post Ml day 2 (low-risk patients) or 3 
(high-risk patients) if clinically stable. Patients not receiving abcx were discharged at the 
treatmg physician’s discretion. Early clinlcal outccmes and safety endpoints within 7 days 
following the index procedure were compared relative to treatment assignment and tim- 
ing of D/C. 
Results- Within the first 72 hours after pnmary PCI, abcx was associated with significant 
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reductions cn the composite endpoint of death, repeat MI. ischemic target vessel revas- 
cularization (TVR), and disabling stroke (3.0% vs. 1.3%, p=O.Ol), largely due to a 
decrease in ischemic TVR (2.4% vs. 0.6%, p=O.O025). Abciximab also reduced early 
subacute thrombosis (1 .O% vs. O.l%, p=O.O06). Among 1703 pts in the U.S., mean times 
of hospital D/C in abcx and non-abcx treated pts were 4.9 + 2.7 days vs. 5.4+ 3.5 days 
respectively, p<O.OOl, and total mean in-hospital costs for the 2 groups were $13,413 
(abcx) vs. $13,000 (no abcx), p=O.13. In the first 7 days following hospital D/C, there 
were no significant differences relative to abcx treatment regarding the composite end- 
point (0.8% vs. 0.3%, p=NS) or its individual elements, nor were differences in major or 
minor bleeding observed. 
Conclusions- Adjunctive abciximab therapy during primary PCI is associated with 
reduced early adverse ischemic outcomes that may facilitate early hospital D/C and 
effect cost sawngs. However, standard times to D/C after primary PCI are now so short 
that efforts to further accelerate DIG with abciximab were for the most part not feasible, 
and cost savings were not realized. 
9:oo a.m. 
871-3 Duration of Cardiopulmonary Bypass and Risk of 
Perioperative Stroke in Coronary Artery Bypass 
Surgery Operations 
Ronald M. Weintraut$ Donald S. Likosky, Cathy S. Ross, Bruce J. Leavitt, Charles A. 
Marnn, David J. Malenka, Louis R. Caplan, Yvon R. Baribeau. Dawd C. Charlesworth, 
Felix Hernandez, Gerald T. O’Connor, Beth Israel Deaconess Medical Center, Boston, 
MA, Northern New England Cardiovascular Disease Study Group, Lebanon, NH 
Background:We previously ldenttfied patient and disease characteristics associated 
with risk of stroke following isolated CABG We hypothesized that duration of cardiopul- 
monary bypass (CPB) is an independent risk factor for stroke. 
Methods We collected data prospectively from 29,406 consecutive patients undergoing 
CABG with CPB between 1992 2000. Stroke was defined as a new focal neurological 
deficit lasting >24 hours. Patients were divided into quartiles by duration of CPB. We 
excluded patients requiring return to CPB and CPB ~30 mln and >=230 min. Direct stan- 
dardization was used to adjust for pre-operative risk factors. 
Results There were 460 (1.56%) strokes. Risk of stroke was twice as great (2.3% vs. 
1 .O%) in the highest quartile than in the lowest (ptrendc 0.001). This increased risk per- 
sisted after adjusting for pre-operative risk factors. 
Conclusion: Increasing duration of CPB was significantly associated with risk of stroke, 
independent of pre-operative risk factors. Possible mechanisms include damage to blood 
elements, increased embolic burden, and difficulty in separation from CPB. 
Table 1: Crude vs. Adjusted Rates of Stroke by Quartile of Cardiopulmonary 
Bypass Duration 
Rates of Strokes 
Quartiles of Pumptime (min) Crude Adjusted” 
<70 1.03 1.13 
70-66 1.23 1.24 
67-106 1.60 1.50 
109-230 2.19 2.06 
*Adjusted for age, sex, diabetes, vascular disease, renal failure or creatinine ,2ms/dl, 
acuity, ejection fraction ~40% 
9:15 a.m. 
871-4 Impact of Coronary Artery Bypass Graft Versus 
Percutaneous Coronary Intervention With Stent on 
Disease-Specific Functional Status in Diabetic and 
Nondiabetic Patients: Results From the SOS Trial 
Zefeng Zhang, Elizabeth M. Mahoney, Rod H. Stables, Jean Booth, Fiona Nugara, John 
A. Spertus, William S. Weintrauh, Emory University School of Medicine, Atlanta, GA 
Background. Previous results from the SOS trial showed a significant benefit of CABG vs 
PCI with Stent on Seattle Angina Questionnaire (SAQ) scores at 6 and 12 mo. Results 
from the BARI trial suggested that for patients (pts) with diabetes (DM), CABG yields 
superior Survival relative to PTCA. The influence of DM on SAQ scores as well as 
whether the relative benefit of CABG vs PCI on SAQ scores applies to DM and non-DM 
pts is not known. Methods. The SOS trial randomized 966 pts with multivessel disease 
from 11196 to 12/99 to CABG (74 DM and 426 non-DM) or PCI with stent (68 DM and 420 
non-DM). We examined the influence of DM on 3 SAQ domains: physlcal limitation (PL), 
angina frequency (AF), and quality of ltfe (QOL) at baseline. 6 and 12 mo. as well as 
whether the relative effect of CABG vs PCI on 6 and 12 mo SAQ scores varied bv DM 
status. SAQ scores range from 0 to 100; higher scores indicate better functioning. All 
analvses were adiusted for slaniflcant covariates. Results. For DM and Non-DM Dts. PL. 
AF and QOL improved significantly after both CABG and PCI at 6 and 12 mo. and CABG 
showed greater gains compared to PCI for most SAQ domains (Non-DM: pcO.01 for 6 
mo PL, AF and QOL. ~~0.02 for 1 yr PL, AF and p=O.O9 for lyr QOL; DM, p=O.O2 for 6 
mo AF, p=O.O9 for 6 mo PL, p>O.lO for other domains). No DM by treatment interaction 
for any SAQ domains was found. Conclusion. While pts with DM tended to have lower 
improvements in PL. CABG appears to confer the same benefits compared to PCI in DM 
and non-DM pts. 
Mean changes for 3 SAQ domams (p-value for DM*treatment mtrractmn) 
SAQ scales 
PL DM 
Non-DM 
AF DM 
Non-DM 
QOL DM 
Non-DM 
6mo 
CABG PCI p CABG 
16.6 10.5 0.55 13.9 
20.3 16.4 16.4 
35.4 27.1 0.66 34.7 
36.2 29.6 37.5 
29.6 26.5 0.65 33.7 
33.2 26.0 35.1 
1 Yr 
PCI p 
10.0 0.94 
14.7 
31.6 0.75 
33.4 
30.1 0.61 
32.5 
9:30 a.m. 
871-5 Lower Preprocedural Hemoglobin Level Is Associated 
With Increased Risk of In-Hospital Mortality Following 
Percutaneous Coronary Intervention 
Ronald S. McKechnie, Cecelia Montoye, Eva Kline-Rogers, Michael J O’Donnell, 
Anthony C. DeFranco, William L. Meengs. Richard McNamara, John G. McGinnity, Kirit 
P&l, David Share, Arthur Riba, Mauro Moscucci, Blue Cross Blue Shield of Michigan 
CardiovascularConsortium, University of Michigan Hospitals, Ann Arbor, Ml 
Background Recent studies have shown a relationship between anemia and in-hospital 
mortality in patients undergoing CABG and with acute myocardial infarction (AMI). The 
prognostic implication of anemia in patients undergoing percutaneous coronary intewen- 
tion (PCI) is unknown. We evaluated the relationship between pre-procedural hemoglo- 
bin (Hgb) level and PCI mortality in a quality controlled regional database. 
Methods: ClInical, procedural, and outcome data on 26,313 consecutwe PCI were pro- 
spectively collected in a consortium of 9 hospitals. Pre-procedure Hgb levels were avail- 
able for 93.3% of patients. Patients were divided into quintiles based on pre-procedural 
Hgb level (g/dl):Ql(6.6-12.3), Q2(12.3-13.5), Q3(13.5-14.4), Q4(14.4-15.4), Qs(l5.4. 
20.1). The primary endpoint was in-hospital mortality. 
Results The in-hospital mortality rate was significantly higher !n 01 when compared to 
other quintiles (Table), (OR 2.4,CI 2.0.3.0,p~O.OOOl). After adjustment for comorbidities, 
Ql remalned an independent predlctor of in-hospital mortality (adjusted OR 1.37,95% Cl 
1.1.1.7,p<O.O2). Analysis of patients undergoing PCI < 24 hours of AMI revealed a higher 
mortality rate I” 01 and Q2 when compared with Q3-05 (pcO.05) (Table). 
Conclusions: Lower pre-procedural Hgb levels are associated with higher in-hospital 
mortality following PCI, particularly in patients within 24 hours of AMI. Whether optimiza- 
tlon of Hgb levels prior to PCI may be of clinical benefit remains to be determined. 
Hgb quintile All PCI patients (n=24,554) PCI with AMI < 24hr (n=3,737) 
Ql 2.9% 11.5% 
Q2 1.6% 9.0% 
1 1% 
Q4 0.9% 4.8% 
05 1.1% 3.6% 
9:45 a.m. 
871-6 Hospital Percutaneous Coronary Intervention Volume 
and Patient Mortality: Is the ACC/AHA Volume Minimum 
Appropriate? 
Andrew J. Epstein Saif S. Rathore, Kevin G. Volpp, Harlan M. Krumholz, Yale University 
School Of Medicine, New Haven. CT, Universih/ of Pennsvlvania Wharton School of 
Bustness. Philadelphia. PA 
Background: To minimize mortality, current ACCIAHA guidelines recommend hospitals 
offering percutaneous coronary interventions (PCls) perform at least 400 PCls annually. 
The appropriateness of this threshold to contemporary practice is unknown. 
Methods: We used data from the Agency for Healthcare Research and Quality 1999 
Nationwide Inpatient Sample, an administrative database of all discharges from a ran- 
dom sample of US hospitals, to assess the association between hospital PCI volume and 
in-hospital mortality. The sample included all PCI recipients age 18 years or older from 
214 hospitals in 22 states (n=ll5,910). Hospitals were grouped by annual PCI volume: 
low (5-l 99, n=55), medium (200.399, n=46). high (400-999, n=60), and very high (21000. 
n=33). We examined the crude association between hospital PCI volume and in-hospital 
mortality using chi-square tests. Multivariate logistic regression with generalized estimat- 
ing equations was used to evaluate the independent association between PCI volume 
